Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE-ESO Tislelizumab in Elderly ESCC Patients Unfit for Chemotherapy
2024-518358-17-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Apr 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of odronextamab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Overall survival at 6 months. Planned start Apr 2025; status: authorised.
02
Drugs
odronextamab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2024-518358-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518358-17-00.